Search the Newsreel

Jasa Kita Berhad acquired KT System Sdn. Bhd. from Norza Holdings Sdn Bhd and Ir. Nazarudin Bin Salleh for MYR 10 million.

Jasper Therapeutics (JSPR) Slips to $0.62 as Stock Tests Key Support - Profit Surge Picks

Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis

This article from TradingKey provides an analysis of Jasper Therapeutics Inc's (JSPR) financial health, focusing on its profitability and balance sheet. It notes the current stock price and market capitalization. The article is part of TradingKey's financial analysis content.

Jasper Therapeutics Inc (JSPR) Earnings Date & Reports & Earnings News

Jasper Therapeutics Inc (JSPR) Income Statement

This article provides the quarterly and annual income statements for Jasper Therapeutics Inc (JSPR), detailing various financial metrics such as operating expenses, R&D expenses, operating profit, and net income from FY2020Q3 to FY2026Q1. It also includes comprehensive FAQs on how to interpret the income …

Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Jasper Therapeutics Inc (JSPR), focusing on volatility, financial risk, and investment risk. It presents various financial metrics including Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, and Liquidity indicators over different timeframes. The data shows significant volatility …

Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis

This article from TradingKey provides a valuation overview for Jasper Therapeutics Inc (JSPR), stating that relevant data for P/E, P/B, and P/CF ratios have not yet been disclosed by the company. It notes a recent stock price of $0.688, down 5.58%, with a market …

Jasper Therapeutics Inc (JSPR) Cash Flow Statement

This article provides detailed quarterly and annual cash flow statements for Jasper Therapeutics Inc (JSPR), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flows and their significance for investors. The company's stock symbol is JSPR, …

Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPR

This article provides a basic overview of Jasper Therapeutics, Inc. (NASDAQ: JSPR) focusing on its financial data and market information available on TradingView. It indicates that the primary content, likely detailed revenue breakdown and other financials, would be accessible through the platform's various tools …

JSPR|Jasper Therapeutics Inc|Price:0.689|Chg%:-0.041

Jasper Therapeutics Inc (JSPR) closed at $0.688 with a 5.58% decrease on July 24, 2026. The company, a clinical-stage biotechnology firm, focuses on developing therapeutics for mast cell-driven diseases and severe combined immunodeficiency, with briquilimab as its lead product candidate. Analysts currently rate JSPR …

Enterprise value to EBITDA forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW

This article focuses on the enterprise value to EBITDA forward for Jasper Therapeutics, Inc. (NASDAQ:JSPRW). It appears to be a financial data snippet from TradingView, indicating specific data points for certain periods. The content itself provides the title and mentions "Period," "Value," "Change," and …

Jasper Therapeutics (JSPR) CMO lists merger-based stock option awards

Jasper Therapeutics' Chief Medical Officer, Greg Keenan, has reported initial equity holdings following the merger with Kira Pharmaceuticals. The holdings include stock options for Voting Common Stock and Non-Voting Convertible Preferred Stock, received in exchange for Kira options. These options start vesting in monthly …

Jasper Therapeutics COO Matthew E. Ros files initial beneficial ownership statement

Jasper Therapeutics COO Matthew E. Ros has filed an initial beneficial ownership statement, reporting stock options for 103,204 voting common shares at a price of USD 0.01. This information was generated using AI based on data from the U.S. Securities and Exchange Commission's EDGAR …

Jasper Therapeutics (JSPR) COO buys non-voting convertible preferred shares

Jasper Therapeutics' Chief Operating Officer, Matthew E. Ros, purchased 881 shares of Non-Voting Convertible Preferred Stock on July 20, 2026, via a private placement. These preferred shares are convertible into 61 shares of Voting Common Stock each, subject to stockholder approval and a beneficial …

Form 4 Jasper Therapeutics Inc For: 22 July By Investing.com

This article reports on a Form 4 filing for Jasper Therapeutics Inc. on July 22. It indicates that the company's stock symbol is JSPR, which experienced a -3.25% change. The content primarily consists of market data and related news beyond the immediate Form 4 …

Jasper Therapeutics (JSPR) COO discloses merger-converted option stakes

Jasper Therapeutics' COO, Matthew E. Ros, reported initial derivative holdings following Kira Pharmaceuticals' merger into a Jasper subsidiary. These holdings include options to purchase 103,204 shares of Jasper voting common stock and 92,278 shares of non

Jasper Therapeutics (JSPR) EVP outlines option and preferred stakes after Kira deal

Jasper Therapeutics EVP Wenru Song has reported her equity positions following the merger of Kira Pharmaceuticals into a Jasper subsidiary. Her holdings include converted Kira options for Jasper's Voting Common Stock and Non-Voting Convertible Preferred Stock, with varying exercise prices and full vesting. Additionally, …

Jasper Therapeutics (JSPR) director details common and preferred stake

Patrick J. Crutcher, a director at Jasper Therapeutics (JSPR), reported his holdings of 518,331 shares of Voting Common Stock and 463,452 shares of Non-Voting Convertible Preferred Stock. The preferred stock is convertible into 61 shares of common stock upon stockholder approval, subject to a …

Jasper Therapeutics (JSPR) director buys preferred stock, granted stock options

Patrick J. Crutcher, a director at Jasper Therapeutics, Inc. (JSPR), recently acquired 888 shares of Non-Voting Convertible Preferred Stock via a private placement on July 20, 2026. These preferred shares will convert into 61 shares of Voting Common Stock each, after stockholder approval, subject …

Jasper Therapeutics merges with Kira Pharmaceuticals

Jasper Therapeutics has completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined entity focused on developing biologic agents for immunologically-driven conditions. The deal is backed by a $132 million private placement and an out-licensing agreement with Mirador Therapeutics, expected to fund operations through …

Jasper Therapeutics stock trades sideways as cash position and clinical pipeline shape outlook

Jasper Therapeutics (JSPR) is an early-stage biotech company trading on Nasdaq, with its stock performance closely tied to its cash reserves, burn rate, and the progress of its clinical pipeline. The company is developing CD117-targeted conditioning agents for hematopoietic stem cell transplantation and gene …

Jasper gets a lifeline in merger with immune drugmaker Kira

Cash-strapped Jasper Therapeutics has merged with privately held Kira Pharmaceuticals in an all-stock acquisition, securing a $132 million private stock offering that extends its operational runway through 2028. This deal allows Jasper to rebound from previous setbacks and expand its pipeline with two immune …

Jasper Closes Kira Deal, Extends Cash Runway

Jasper Therapeutics has completed its all-stock acquisition of Kira Pharmaceuticals, enhancing its pipeline of therapies for immune-mediated diseases. This merger, combined with a $132 million private placement, extends Jasper's cash runway through the second half of 2028. The company plans to advance several key …

12 Health Care Stocks Moving In Friday's Intraday Session

This article lists 12 health care stocks experiencing significant price movements during Friday's intraday trading. It details six gainers, including Jasper Therapeutics and Kalaris Therapeutics, with their percentage increases, stock prices, and market capitalizations. The article also covers six losers, such as Agape ATP …

Patrick Crutcher appointed to Jasper Therapeutics board; Matthew Ros named COO

Jasper Therapeutics (JSPR) has announced two key appointments: Patrick Crutcher to its board of directors and Matthew Ros as Chief Operating Officer. These changes are effective immediately following the Effective Time on July 16, 2026, and are in accordance with a merger agreement. Both …

Jasper Therapeutics (NASDAQ: JSPR) buys Kira, adds $132M PIPE cash

Jasper Therapeutics (NASDAQ: JSPR) announced the all-stock acquisition of Kira Pharmaceuticals and concurrently secured $132 million in PIPE financing. This strategic move is expected to significantly dilute pre-transaction Jasper equity holders but aims to fund multiple clinical milestones and operating needs through the second …

Jasper buys time with Kira merger and $132M PIPE lifeline

The article discusses Jasper's merger with Kira and a $132 million PIPE (Private Investment in Public Equity) lifeline. This strategic move aims to provide Jasper with additional resources and time, addressing financial challenges and enhancing its market position. The merger and investment are critical …

Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy

Jasper Therapeutics has released an investor presentation detailing its all-stock merger with Kira Pharmaceuticals, accompanied by a $132 million PIPE financing. The deal outlines an ownership split favoring legacy Kira holders and PIPE investors, with Jasper holders receiving a contingent value right. Proceeds from …

Jasper Therapeutics completes Kira acquisition, secures $132M financing to fund pipeline into H2 2028

Jasper Therapeutics has completed an all-stock acquisition of Kira Pharmaceuticals and concurrently secured $132 million in financing. This funding, along with proceeds from out-licensed assets, is expected to finance combined operations and multiple clinical milestones through the second half of 2028. The company plans …

Jasper Merger Brings Three Drug Candidates for Immune Disorders

Jasper Therapeutics has completed an all-stock acquisition of Kira Pharmaceuticals, creating a combined company focused on developing biologic therapies for immunologically-driven disorders. Concurrently, Jasper secured approximately $132 million in a private placement and out-licensed two assets for $12 million, extending its cash runway through …

Press Release: Jasper Therapeutics Announces Merger With Kira Pharmaceuticals

Jasper Therapeutics and Kira Pharmaceuticals have announced a definitive merger agreement. The combined company will focus on advancing Kira's pipeline of complement-guided therapies for immune-mediated diseases, including a lead asset, KP104, nearing Phase 3 trials. The merger aims to create a clinical-stage biotechnology company …

Jasper Therapeutics (NASDAQ: JSPR) closes Kira merger and $132M preferred financing

Jasper Therapeutics (NASDAQ: JSPR) has completed its all-stock acquisition of Kira Pharmaceuticals and secured approximately $132 million in preferred stock financing. This merger combines Kira's complement-therapy assets (KP-104, KP-701) with Jasper's briquilimab program, creating a consolidated pipeline focused on immunologically-driven disorders. The financing, along …

Santander (SANB11), Lojas Renner (LREN3), Itaú (ITUB4) e outros destaques desta segunda (13)

Jash Engineering Targets 4x Revenue Growth Within 4 Years Driven by Export Surge

Jash Engineering Aims for 3 to 4 Times Growth in Next 3 to 4 Years

Jash Engineering books Rs 91 Cr orders in June 2026